Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study.
There has been minimal clinical experience with the use of the Aspergillus galactomannan enzyme-linked immunosorbent assay (ELISA) for patients receiving echinocandin therapy. We reviewed the experience with the galactomannan ELISA for 17 patients in a study of caspofungin treatment for invasive aspergillosis. The rate of successful outcomes for these patients was similar to that overall for participants in the study. Trends in antigenemia levels correlated with clinical and radiographic findings.
Maertens
Johan
J
University Hospital Gasthuisberg, Leuven, Belgium.
Glasmacher
Axel
A
Selleslag
Dominik
D
Ngai
Angela
A
Ryan
Desmond
D
Layton
Melissa
M
Taylor
Arlene
A
Sable
Carole
C
Kartsonis
Nicholas
N
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000097:blood*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D000077336:Caspofungin; D054714:Echinocandins; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D055666:Lipopeptides; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000382:microbiology; D008351:Mannans / Q000097:blood*; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D016896:Treatment Outcome
D000935:Antifungal Agents; D000946:Antigens, Fungal; D054714:Echinocandins; D055666:Lipopeptides; D008351:Mannans; D010456:Peptides, Cyclic; C012990:galactomannan; D000077336:Caspofungin; D005690:Galactose